{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:00:59Z","timestamp":1793642459747,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.anai.2022.10.025","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T22:58:24Z","timestamp":1667602704000},"page":"178-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Interleukin-6 and cytokine release syndrome"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-2067","authenticated-orcid":false,"given":"Erika Yue","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Jakubovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2022.10.025_bib0001","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2222.1988.tb02904.x","article-title":"Immediate hypersensitivity reactions to penicillin and related antibiotics","volume":"18","author":"Weiss","year":"1988","journal-title":"Clin Allergy"},{"issue":"2 suppl 2","key":"10.1016\/j.anai.2022.10.025_bib0002","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jaci.2009.10.028","volume":"125","author":"Khan","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"4 Pt 2","key":"10.1016\/j.anai.2022.10.025_bib0003","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0091-6749(05)80222-2","article-title":"Tryptase, a mediator of human mast cells","volume":"86","author":"Schwartz","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.10.025_bib0004","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.jaip.2021.03.011","article-title":"Use and interpretation of acute and baseline tryptase in perioperative hypersensitivity and anaphylaxis","volume":"9","author":"Vitte","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Suppl 2","key":"10.1016\/j.anai.2022.10.025_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13223-018-0289-y","article-title":"Drug allergy","volume":"14","author":"Warrington","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"9S","key":"10.1016\/j.anai.2022.10.025_bib0006","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic mAb: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.10.025_bib0008","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/all.14644","article-title":"Interleukin-6: a novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association","volume":"76","author":"Jakubovic","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity reactions to BioLogicals: an EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2022.10.025_bib0010","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.anai.2020.04.005","article-title":"Drug hypersensitivity in the fast lane: what clinicians should know about phenotypes, endotypes, and biomarkers","volume":"124","author":"Jakubovic","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.10.025_bib0011","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1182\/blood.V59.5.1036.1036","article-title":"Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia","volume":"59","author":"Dillman","year":"1982","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.anai.2022.10.025_bib0012","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1056\/NEJM198905253202117","article-title":"Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]","volume":"320","author":"Chatenoud","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2022.10.025_bib0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15274","article-title":"How i treat primary haemophagocytic lymphohistiocytosis","volume":"182","author":"Marsh","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0014","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"21","key":"10.1016\/j.anai.2022.10.025_bib0015","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.3390\/jcm10215190","article-title":"Cytokine release syndrome in the immunotherapy of hematological malignancies: the biology behind and possible clinical consequences","volume":"10","author":"Tvedt","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2022.10.025_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.611366","article-title":"Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.10.025_bib0018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/eci.09.31","article-title":"Monoclonal antibody-induced cytokine-release syndrome","volume":"5","author":"Bugelski","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.10.025_bib0019","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2022.10.025_bib0020","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.anai.2022.10.025_bib0021","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.10.025_bib0022","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.anai.2022.10.025_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","article-title":"Reactions to rituximab in an outpatient infusion center: a 5-year review","volume":"5","author":"Levin","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2022.10.025_bib0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.50","article-title":"Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents","volume":"18","author":"Szebeni","year":"2001","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"3","key":"10.1016\/j.anai.2022.10.025_bib0026","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2022.10.025_bib0027","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3389\/fimmu.2018.03027","article-title":"Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions","volume":"9","author":"Porebski","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.anai.2022.10.025_bib0028","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.anai.2022.10.025_bib0030","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to mAb","volume":"5","author":"Picard","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaip.2019.09.017","article-title":"Diagnosis and management of patients with the \u03b1-gal syndrome","volume":"8","author":"Platts-Mills","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2022.10.025_bib0032","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents","volume":"7","author":"Madrigal-Burgaleta","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2022.10.025_bib0033","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.10.025_bib0034","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.anai.2022.10.025_bib0036","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.5415\/apallergy.2022.12.e9","article-title":"Cytokine release syndrome - a unique entity of augmentin hypersensitivity reaction","volume":"12","author":"Tan","year":"2022","journal-title":"Asia Pac Allergy"},{"issue":"6","key":"10.1016\/j.anai.2022.10.025_bib0037","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/ACI.0b013e3280108716","article-title":"Desensitization for drug allergy","volume":"6","author":"Castells","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.10.025_bib0038","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and mAb","volume":"4","author":"Sloane","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2022.10.025_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.785259","article-title":"Converter phenotype: a new profile that is not exclusive to Taxanes","volume":"2","author":"Jimenez-Rodriguez","year":"2022","journal-title":"Front Allergy"},{"issue":"2","key":"10.1016\/j.anai.2022.10.025_bib0040","doi-asserted-by":"crossref","first-page":"AB34","DOI":"10.1016\/j.jaci.2018.12.105","article-title":"Adverse reactions during desensitization to chemotherapy agents","volume":"143","author":"Fernandez","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.10.025_bib0041","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0091-6749(83)90083-0","article-title":"Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin","volume":"71","author":"Naclerio","year":"1983","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2022.10.025_bib0042","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jaci.2004.08.037","article-title":"Loss of syk kinase during IgE-mediated stimulation of human basophils","volume":"114","author":"Macglashan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.10.025_bib0043","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1081-1206(10)61136-2","article-title":"Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen","volume":"94","author":"Morales","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.10.025_bib0044","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/eji.201040810","article-title":"Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting Fc\u03b5RI internalization","volume":"41","author":"Sancho-Serra Mdel","year":"2011","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.anai.2022.10.025_bib0045","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00262-012-1273-x","article-title":"Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization","volume":"61","author":"Castells","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.anai.2022.10.025_bib0046","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.anai.2022.10.025_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100707","article-title":"Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes","volume":"45","author":"England","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.anai.2022.10.025_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613422","article-title":"Interleukin-6 Is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia","volume":"12","author":"Santa Cruz","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.10.025_bib0049","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.anai.2022.10.025_bib0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"1","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.10.025_bib0051","doi-asserted-by":"crossref","first-page":"AB100","DOI":"10.1016\/j.jaci.2019.12.615","article-title":"Biomarkers associated with hypersensitivity reactions to chemotherapeutic agents","volume":"145","author":"Fernandez","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2022.10.025_bib0052","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine storm in COVID-19: the current evidence and treatment strategies","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.anai.2022.10.025_bib0053","doi-asserted-by":"crossref","first-page":"e12086","DOI":"10.1002\/clt2.12086","article-title":"Omalizumab for successful chemotherapy desensitisation: what we know so far","volume":"11","author":"Bumbacea","year":"2021","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"10.1016\/j.anai.2022.10.025_bib54","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622019056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622019056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:30:51Z","timestamp":1761053451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622019056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1081120622019056"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.10.025","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 and cytokine release syndrome","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}